Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients

Eric M. Liotta, Ayush Batra, Jeffrey R. Clark, Nathan A. Shlobin, Steven C. Hoffman, Zachary S. Orban & Igor J. Koralnik

Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Abstract

Objective: Covid-19 can involve multiple organs including the nervous system. We sought to characterize the neurologic manifestations, their risk factors, and associated outcomes in hospitalized patients with Covid-19. Methods: We examined neurologic manifestations in 509 consecutive patients admitted with confirmed Covid-19 within a hospital network in Chicago, Illinois. We compared the severity of Covid-19 and outcomes in patients with and without neurologic manifestations. We also identified independent predictors of any neurologic manifestations, encephalopathy, and functional outcome using binary logistic regression. Results: Neurologic manifestations were present at Covid-19 onset in 215 (42.2%), at hospitalization in 319 (62.7%), and at any time during the disease course in 419 patients (82.3%). The most frequent neurologic manifestations were myalgias (44.8%), headaches (37.7%), encephalopathy (31.8%), dizziness (29.7%), dysgeusia (15.9%), and anosmia (11.4%). Strokes, movement disorders, motor and sensory deficits, ataxia, and seizures were uncommon (0.2 to 1.4% of patients each). Severe respiratory disease requiring mechanical ventilation occurred in 134 patients (26.3%). Independent risk factors for developing any neurologic manifestation were severe Covid-19 (OR 4.02; 95% CI 2.04–8.89; P < 0.001) and younger age (OR 0.982; 95% CI 0.968–0.996; P = 0.014). Of all patients, 362 (71.1%) had a favorable functional outcome at discharge (modified Rankin Scale 0–2). However, encephalopathy was independently associated with worse functional outcome (OR 0.22; 95% CI 0.11–0.42; P < 0.001) and higher mortality within 30 days of hospitalization (35 [21.7%] vs. 11 [3.2%] patients; P < 0.001). Interpretation: Neurologic manifestations occur in most hospitalized Covid-19 patients. Encephalopathy was associated with increased morbidity and mortality, independent of respiratory disease severity.

Introduction

As of 8 September 2020, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has led to over 26.5 million confirmed infections and 875,000 deaths from coronavirus disease-2019 (Covid-19) worldwide.1

Like most infections caused by members of the coronavirus family, SARS-CoV-2 manifests itself with upper respiratory tract infections and flu-like symptoms of varying severity.2 However, Covid-19 is unique in its ability to cause a multi-organ disease, with involvement of the central and peripheral nervous system in some individuals. Indeed, a wide range of neurologic manifestations of SARS-CoV-2 infection have been recognized, and evidence of their severity and persistence is increasing.3–10 However, the frequency of those manifestations and associated risk factors remain unclear. We sought to characterize the incidence of neurologic manifestations, in patients with confirmed Covid-19 and identify factors associated with the development of neurologic manifestations in hospitalized patients with both severe and non-severe respiratory disease. Furthermore, neurologic manifestations, especially encephalopathy, have been associated with worse clinical outcomes in other systemic illnesses including sepsis and may even lead to significant

Correspondence
Igor J. Koralnik, Northwestern University Feinberg School of Medicine, Chicago, IL.
Tel: +1 (312) 503 1345; Fax: +1 (312) 503 3950; E-mail: Igor.koralnik@northwestern.edu

Funding Information
Dr. Liotta is supported by National Institutes of Health grant L30 NS098427.

Received: 9 September 2020; Accepted: 10 September 2020

Annals of Clinical and Translational Neurology 2020; 7(11): 2221–2230
doi: 10.1002/acn3.51210

Contributed equally.
disability.\textsuperscript{11,12} Therefore, we sought to identify if encephalopathy was associated with greater morbidity in hospitalized patients with Covid-19.

**Subjects/Materials and Methods**

**Patients**

We retrospectively analyzed the first consecutive patients admitted with Covid-19 to the Northwestern Medicine Healthcare (NMHC) system between 5 March and 6 April 2020. NMHC consists of one academic medical center (AMC) and nine other hospitals in the Chicago area. Covid-19 diagnosis was confirmed by SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) assay of nasopharyngeal swab or broncho-alveolar lavage fluid. All laboratory and radiologic assessments were performed as part of routine clinical care. This study was approved by our institutional review board (STU00212627) with waiver of consent for retrospective analysis.

**Procedures**

Demographic, medical comorbidity, pre-hospitalization medication usage, and hospital course data were collected by electronic medical record review. Laboratory data were collected by automated electronic query. Neurologic manifestations were identified by review of clinical notes, diagnostic studies, and physician-documented diagnoses. The identification of neurologic manifestations, the dates of neurologic manifestation onset, and Covid-19 symptom onset dates was facilitated by electronic note templates implemented in the NMHC System as part of the Covid-19 response. In particular, encephalopathy was identified by (a) report of altered mental status or depressed level of consciousness, (b) physician documented diagnosis of encephalopathy or the delirium encephalopathy syndrome, or (c) positive Confusion Assessment Method (CAM) evaluation. The Confusion Assessment Method is a well-validated and widely used clinical and research tool for the identification of the delirium encephalopathy syndrome and has been in routine clinical use at NMHC since 2008.\textsuperscript{13–15} Neurologic manifestations were included starting on the date of Covid-19 onset, as identified by the patient’s clinical provider, through 90 days. In cases where neurologic manifestations were not specifically attributed to a documented diagnosis, the cases were independently adjudicated by two separate neurologists (AB and EML). A third neurologist independently reviewed the chart to serve as a tie-breaker (IJK) in cases of disagreement. In those cases where neurologic manifestations were attributed to a specific neurologic diagnosis (e.g., stroke), the patient was recorded as having that specific diagnosis rather than each component neurologic manifestation. Patients were dichotomized into severe versus non-severe Covid-19 respiratory disease based on the need for mechanical ventilation during hospitalization; this criterion was used to account for the possibility of delayed clinical deterioration after hospital admission.

Functional outcome at hospital discharge was extracted from therapy and rehabilitation medicine physician documentation using the modified Rankin Scale (mRS) categorized as: mRS 0–2, able to look after ones’ own affairs without assistance; mRS 3, ambulates unassisted but needs help with ones’ own affairs; mRS 4–5, unable to ambulate unassisted and needs assistance for bodily care; and mRS 6, death. The discharge mRS scores were determined independently by two reviewers and disagreements were reconciled by majority decision after review (EML).

**Statistical analysis**

Data were summarized as number of patients (frequency), mean (standard deviation) for normally distributed variables, and median (interquartile range [IQR]) for non-normally distributed variables. Associations were assessed using Fisher’s exact test, Spearman’s rank correlation test, and Wilcoxon rank-sum test. Binary logistic regression models were developed to identify adjusted predictors of: (1) experiencing any neurologic manifestations, (2) experiencing encephalopathy, and (3) having a favorable discharge functional outcome (mRS 0–2). In each case, we first developed a model using \textit{a priori} variables based on biologic plausibility and review of the recent Covid-19 literature. Then we developed models using the \textit{a priori} variables plus additional variables univariately associated with the model outcome at $P \leq 0.15$ and not highly collinear with a variable already included. To avoid overfitting models to the data, we used a backward variable selection algorithm based on Akaike Information Criteria optimization to develop final \textit{parsimonious} adjusted models. Details of the \textit{a priori} and \textit{parsimonious} models, including the \textit{a priori} variables for each model, are included in the Table S2. We also developed an \textit{a priori} binary logistic regression model for the association between encephalopathy and 30-day mortality adjusted for age, severe Covid-19 disease, and hospitalization at the AMC; limited numbers of patient deaths prevented inclusion of additional variables for adjustment. Two-sided $P \leq 0.05$ was considered significant and all analyses were performed in R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results

Frequency of neurologic manifestations

There were 509 consecutive patients included in the study (age 58.5 ± 16.9 years, 281 (55.2%) males), and 134 (26.3%) had severe Covid-19 requiring mechanical ventilation. Neurologic manifestations were present at Covid-19 onset in 215 patients (42.2%), at hospital admission in 319 patients (62.7%) and at any time during the disease course in 419 patients (82.3%). The most frequent neurologic manifestations were myalgias (228, 44.8%), headaches (192, 37.7%), encephalopathy (162, 31.8%), dizziness (151, 29.7%), dysgeusia (81, 15.9%), and anosmia (58, 11.4%). In addition, reports of generalized fatigue (214 [42.9%] patients) at onset and any time during Covid-19 disease (404 [79.4%] patients) were common. The clinical characteristics of the patients with and without any neurologic manifestations or encephalopathy are summarized in Table 1. Patients presenting with any neurologic manifestations were younger than those without (57.53 [16.31] vs. 62.98 [18.97] years; P = 0.005) and had a longer time from COVID onset to hospitalization (7 [4, 10] vs. 5 [2, 9] days; P = 0.003). Conversely, patients with encephalopathy were older than those without (65.51 [16.54] vs. 55.22 [16.10] years; P < 0.001), had a shorter time from COVID onset to hospitalization (6 [3, 9] vs. 7 [4, 10] days; P = 0.014), were more likely to be male, and to have a history of any neurological disorder, cancer, cerebrovascular disease, chronic kidney disease, diabetes, dyslipidemia, heart failure, hypertension and smoking in assessments without multivariate adjustment. There were no differences in use of angiotensin converting enzyme (ACE) inhibitors, angiotensin 2 receptor blocker (ARB), corticosteroids or immunosuppressants prior to admission in patients with and without any neurologic manifestations or encephalopathy (Table S1).

Timing of neurologic manifestations by Covid-19 severity

Table 2 summarizes the neurologic manifestations that occurred at onset and any time during Covid-19. Patients with severe disease had a higher frequency of neurologic manifestations (124 [92.5%] vs. 295 [78.9%], P = 0.001), which resulted primarily from a higher frequency of encephalopathy in severe Covid-19 (113 [84.3%] vs. 49 [13.1%] patients, P < 0.001).

Myalgias, headache, encephalopathy, dizziness, dysgeusia, and anosmia together accounted for 95.8% of all neurologic manifestations at Covid-19 onset and 91.4% during the course of the disease. Conversely, ischemic and hemorrhagic stroke, movement disorders, focal motor and sensory deficits, ataxia, and seizures were uncommon, affecting between 0.2 and 1.4% of patients each. No cases of Guillain-Barre syndrome or acute demyelinating encephalomyelitis (ADEM) were identified. The median number of neurologic manifestations per patient was 2 [1, 3].

Laboratory markers in Covid-19 patients with and without neurologic manifestations

Table 3 summarizes serum laboratory results evaluating inflammation routinely performed in Covid-19 patients in our system, stratified by presence of any neurologic manifestations or encephalopathy. Only patients with encephalopathy had higher white blood cell count, C-reactive protein, D-dimer, ferritin, and procalcitonin levels than those without encephalopathy; however, these associations did not remain after adjustment in the logistic regression model of encephalopathy (Fig. 1A).

Parsimoniously adjusted models of neurologic manifestations

In a parsimoniously adjusted model, younger patients (adjusted OR 0.982; 95% CI 0.968, 0.996 per year; P = 0.014) and those with severe Covid-19 disease (adjusted OR 4.02; 95% CI 2.04, 8.89; P < 0.001) were more likely to develop any neurologic manifestations (Table S2). In contrast, older patients were more likely to develop encephalopathy (adjusted OR 1.06; 95% CI 1.04, 1.08 per year; P < 0.001). The parsimoniously adjusted model of encephalopathy also suggested that severe Covid-19 disease (adjusted OR 131; 95% CI 61.2, 310; P < 0.001), a history of any neurological disorder or chronic kidney disease, lower admission serum white blood cell count, and shorter time from Covid-19 onset to hospitalization were associated with greater likelihood of encephalopathy (Fig. 1A). Due in part to logistical challenges and restrictions on diagnostic testing due to pandemic infection prevention measures, the specific pathophysiology of the neurologic manifestations was not established with certainty in the majority of cases. For instance, in-person neurology or neurological consultation was obtained only in 30 (5.9%), brain CT in 46 (9.0%), brain MRI in 16 (3.1%), electroencephalograms in 6 (1.2%), and lumbar puncture in 2 (0.4%) of the 509 patients.

Differences between the Academic Medical Center (AMC) and other hospitals of the network

Table 4 summarizes the differences between 254 (49.9%) patients treated at our AMC versus the other nine
hospitals in our system. Patients at the AMC were younger but had greater comorbidities and were more often black or African American, consistent with our regional demographics. Patients at the AMC more often had neurologic manifestations at the time of hospitalization and had an overall higher frequency of neurologic manifestations during the course of Covid-19; however, there was no significant difference in the occurrence of

Table 1. Patient characteristics by presence of neurologic manifestations and encephalopathy.

| Overall | No Neurologic Manifestation | Any Neurologic Manifestation | No Encephalopathy | Encephalopathy | P       |
|---------|-----------------------------|-----------------------------|-------------------|---------------|---------|
| n       | 509                         | 90                          | 419               | 347           | 162     |
| Age, years (mean (SD)) | 58.51 (16.93) | 62.98 (18.97) | 57.53 (16.31) | 0.005 | 55.22 (16.10) | 65.51 (16.54) | <0.001 |
| Male, n (%) | 281 (55.2) | 50 (55.6) | 231 (55.1) | 1 | 180 (51.9) | 101 (62.3) | 0.034 |
| Female, n (%) | 228 (44.8) | 40 (44.4) | 188 (44.9) | 0.227 | 167 (48.1) | 61 (37.7) |
| Race, n (%) | | | | | | | 
| White | 268 (52.7) | 56 (62.2) | 212 (50.6) | 0.172 | 172 (49.6) | 96 (59.3) | 
| Black or African American | 151 (29.7) | 26 (28.9) | 125 (29.8) | 114 (32.9) | 37 (22.8) |
| Asian | 18 (3.5) | 2 (2.2) | 16 (3.8) | 12 (3.5) | 6 (3.7) |
| Native Hawaiian or Other Pacific Islander | 1 (0.2) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 1 (0.6) |
| Other | 53 (10.4) | 3 (3.3) | 50 (11.9) | 0.005 | 37 (10.7) | 16 (9.9) |
| Unknown | 1 (0.2) | 0 (0.0) | 1 (0.2) | 1 (0.3) | 0 (0.0) |
| Declined to provide | 17 (3.3) | 3 (3.3) | 14 (3.3) | 11 (3.2) | 6 (3.7) |
| Ethnicity, n (%) | | | | | | | 
| Not Hispanic or Latino | 384 (75.4) | 75 (83.3) | 309 (73.7) | 263 (75.8) | 121 (74.7) |
| Hispanic or Latino | 107 (21.0) | 11 (12.2) | 96 (22.9) | 75 (21.6) | 32 (19.8) |
| Declined to Provide | 18 (3.5) | 4 (4.4) | 14 (3.3) | 9 (2.6) | 9 (5.6) |
| Time from COVID Onset to Hospitalization, days (median [IQR]) | 7.00 | 5.00 | 7.00 | 0.003 | 7.00 | 6.00 | 0.014 |
| Hospitalized at the Academic Medical Center, n (%) | 254 (49.9) | 32 (35.6) | 222 (53.0) | 0.004 | 168 (48.4) | 86 (53.1) | 0.375 |
| Medical Comorbidities | | | | | | | 
| History of Any Neurological Disorder, n (%) | 134 (26.3) | 27 (30.0) | 107 (25.5) | 0.459 | 79 (22.8) | 55 (34.0) | 0.010 |
| Cancer, n (%) | 61 (12.0) | 10 (11.1) | 51 (12.2) | 0.147 | 29 (8.4) | 32 (19.8) | <0.001 |
| Cerebrovascular Disease, n (%) | 39 (7.7) | 12 (13.3) | 27 (6.4) | 0.044 | 18 (5.2) | 21 (13.0) | 0.004 |
| Chronic Kidney Disease, n (%) | 56 (11.0) | 10 (11.1) | 46 (11.0) | 1 | 29 (8.4) | 27 (16.7) | 0.008 |
| Diabetes Mellitus, n (%) | 154 (30.3) | 31 (34.4) | 123 (29.4) | 0.008 | 408 (95.7) | 59 (36.4) | 0.049 |
| Dyslipidemia, n (%) | 172 (33.8) | 32 (35.6) | 140 (33.4) | 0.789 | 100 (28.8) | 72 (44.4) | 0.001 |
| Heart Failure, n (%) | 36 (7.1) | 7 (7.8) | 29 (6.9) | 0.051 | 14 (4.0) | 22 (13.6) | <0.001 |
| Hypertension, n (%) | 277 (54.4) | 55 (61.1) | 222 (53.0) | 0.198 | 169 (48.7) | 108 (66.7) | <0.001 |
| Organ transplantation, n (%) | 16 (3.1) | 2 (2.2) | 14 (3.3) | 0.827 | 7 (2.0) | 9 (5.6) | 0.063 |
| Peripheral Vasc. Disease, n (%) | 10 (2.0) | 4 (4.4) | 6 (1.4) | 0.147 | 4 (1.2) | 6 (3.7) | 0.112 |
| Smoking, n (%) | 140 (27.5) | 22 (24.4) | 118 (28.2) | 0.008 | 58 (33.9) | 57 (35.2) | 0.011 |
| Patient outcomes | | | | | | | 
| Hospital length of stay, days (median [IQR]) | 7.00 | 5.00 | 8.00 | <0.001 | 5.00 | 17.00 | <0.001 |
| Modified Rankin Scale Score at Hospital Discharge, n (%) | 0.093 | | | | | | <0.001 |
| 0 to 2: Looks after own affairs without assistance | 362 (71.1) | 63 (70.0) | 299 (71.4) | 310 (89.3) | 52 (32.1) |
| 3: Ambulates unassisted, needs some help with own affairs | 47 (9.2) | 5 (5.6) | 42 (10.0) | 18 (5.2) | 29 (17.9) |
| 4 to 5: Unable to ambulate unassisted, needs assistance with own bodily care | 57 (11.2) | 9 (10.0) | 48 (11.5) | 8 (2.3) | 49 (30.2) |
| 6: dead | 43 (8.4) | 13 (14.4) | 30 (7.2) | 11 (3.2) | 32 (19.8) |
| 30-day mortality, n (%) | 46 (9.1) | 13 (14.4) | 33 (7.9) | 0.079 | 11 (3.2) | 35 (21.7) | <0.001 |
### Table 2. Timing of neurologic manifestations by Covid-19 severity.

|                          | At time of Covid-19 symptom onset | Any time during Covid-19 |
|--------------------------|----------------------------------|--------------------------|
|                          | Overall                          | Non-severe Covid-19 disease | Severe Covid-19 disease | Overall                          | Non-severe Covid-19 disease | Severe Covid-19 disease |
|                          | N                                |                          |                          | P                                |                          |                          |
| Any neurologic           | 509                              | 375                      | 134                      | 509                              | 375                      | 134                      |
| manifestations n(%)      | 215 (42.2)                       | 160 (42.7)               | 55 (41.0)                | 0.822                            | 419 (82.3)               | 295 (78.7)               | 124 (92.5)               | 0.001                            |
| Number of neurologic     |                                  |                          |                          |                                  |                          |                          |                          |                                  |
| manifestations n(%)      |                                  |                          |                          | 0.595                            | <0.001                   |
| 0                        | 294 (57.8)                       | 215 (57.3)               | 79 (59.0)                |                                  |                          |                          |                          |                                  |
| 1                        | 145 (28.5)                       | 106 (28.3)               | 39 (29.1)                |                                  |                          |                          |                          |                                  |
| 2                        | 53 (10.4)                        | 39 (10.4)                | 14 (10.4)                |                                  |                          |                          |                          |                                  |
| 3                        | 13 (2.6)                         | 12 (3.2)                 | 1 (0.7)                  |                                  |                          |                          |                          |                                  |
| 4 or more                | 4 (0.8)                          | 3 (0.8)                  | 1 (0.7)                  |                                  |                          |                          |                          |                                  |
| Myalgias n (%)           | 134 (26.4)                       | 99 (26.6)                | 35 (26.1)                | 1                                | 228 (44.8)               | 172 (45.9)               | 56 (41.8)                | 0.476                            |
| Headache n (%)           | 84 (16.5)                        | 64 (17.1)                | 20 (14.9)                | 0.662                            | 192 (37.7)               | 149 (39.7)               | 43 (32.1)                | 0.143                            |
| Encephalopathy n (%)     | 9 (1.8)                          | 8 (2.1)                  | 1 (0.7)                  | 0.507                            | 162 (31.8)               | 49 (13.1)                | 113 (84.3)               | <0.001                           |
| Dizziness/Vertigo n (%)  | 26 (5.1)                         | 24 (6.4)                 | 2 (1.5)                  | 0.047                            | 151 (29.7)               | 111 (29.6)               | 40 (29.9)                | 1                                |
| Dysgeusia n (%)          | 24 (4.7)                         | 17 (4.5)                 | 7 (5.2)                  | 0.931                            | 81 (15.9)                | 64 (17.1)                | 17 (12.7)                | 0.293                            |
| Anosmia n (%)            | 18 (3.5)                         | 14 (3.7)                 | 4 (3.0)                  | 0.897                            | 58 (11.4)                | 47 (12.5)                | 11 (8.2)                 | 0.233                            |
| Syncope n (%)            | 6 (1.2)                          | 4 (1.1)                  | 2 (1.5)                  | 1                                | 22 (4.3)                 | 15 (4.0)                 | 7 (5.2)                  | 0.726                            |
| Rhabdomyolysis n (%)     | 2 (0.4)                          | 1 (0.3)                  | 1 (0.7)                  | 1                                | 18 (3.5)                 | 5 (1.3)                  | 13 (12.7)               | <0.001                           |
| Orthostatic hypotension n (%) | —  | —  | —  | —  | 16 (3.1) | 10 (2.7) | 6 (4.5) | 0.458                           |
| Ischemic stroke n (%)    | —  | —  | —  | —  | 7 (1.4) | 2 (0.5) | 5 (3.7) | 0.222                            |
| Movement disorder n (%)  | 1 (0.2)                         | 1 (0.3)                  | 0 (0.0)                  | 1                                | 4 (0.8)                  | 2 (0.5)                  | 2 (1.5)                  | 0.610                            |
| Seizure n (%)            | 2 (0.4)                         | 2 (0.5)                  | 0 (0.0)                  | 0.966                            | 4 (0.8)                  | 4 (1.1)                  | 0 (0.0)                  | 0.528                            |
| Focal motor deficits n (%) | —  | —  | —  | —  | 3 (0.6) | 2 (0.5) | 1 (0.7) | 1                                |
| Ataxia n (%)             | —  | —  | —  | —  | 2 (0.4) | 1 (0.3) | 1 (0.7) | 1                                |
| Polyneuropathy n (%)     | —  | —  | —  | —  | 2 (0.4) | 0 (0.0) | 2 (1.5) | 0.117                            |
| Encephalitis n (%)       | —  | —  | —  | —  | 1 (0.2) | 1 (0.3) | 0 (0.0) | 1                                |
| Focal sensory deficits n (%) | —  | —  | —  | —  | 1 (0.2) | 0 (0.0) | 1 (0.7) | 0.591                            |
| Hemorrhagic stroke n (%) | —  | —  | —  | —  | 1 (0.2) | 0 (0.0) | 1 (0.7) | 0.591                            |
| Polyradiculitis n (%)    | 1 (0.2)                         | 0 (0.0)                  | 1 (0.7)                  | 0.591                            | 1 (0.2)                  | 0 (0.0)                  | 1 (0.7)                  | 0.591                            |

### Table 3. Hospital Admission Laboratory markers of inflammation in Covid-19 patients with and without neurologic manifestations.

|                          | Overall                          | No neurologic manifestation | Any neurologic manifestation | P | No encephalopathy | Encephalopathy | P |
|--------------------------|----------------------------------|------------------------------|------------------------------|---|------------------|----------------|---|
| n                        | 509                              | 90                           | 419                          | 347                          | 162              |               |   |
| White blood cell, (median [IQR]), Reference: 3.5–10.5 1000µL | 6.3 [4.6, 8.3] | 6.3 [4.4, 9.4] | 6.3 [4.7, 8.2] | 0.863 | 5.9 [4.6, 7.7] | 6.9 [5.0, 9.4] | 0.001 |
| Platelet, (median [IQR]), Reference: 140–390 1000µL | 199 [162, 249] | 206 [170, 248] | 198 [162, 249] | 0.542 | 200 [165, 247] | 199 [159, 255] | 0.68 |
| C-Reactive Protein, (median [IQR]), Reference: 0.0–0.5 mg/dL | 10.45 | 10.15 | 10.60 | 0.948 | 9.40 | 13.80 | 0.033 |
| D-dimer, (median [IQR]), Reference: 0–230 ng/mL | 296 [185, 583] | 332 [192, 595] | 285 [184, 570] | 0.568 | 265 [166, 448] | 436 [240, 847] | <0.001 |
| Ferritin, (median [IQR]), Reference: 24–336 ng/mL | 448 [196, 949] | 398 [159, 738] | 468 [205, 976] | 0.153 | 352 [187, 816] | 633 [257, 1244] | 0.002 |
| Procalcitonin, (median [IQR]), Reference: ≤0.065 ng/mL | 0.10 [0.02, 0.24] | 0.10 [0.02, 0.39] | 0.10 [0.02, 0.24] | 0.757 | 0.07 [0.02, 0.18] | 0.17 [0.08, 0.41] | <0.001 |
encephalopathy. Chronic medications prior to hospitalization and experimental treatments provided during hospitalization are listed in Table S3. Rates of mechanical ventilation were similar between the AMC and the other hospitals; however, do not resuscitate, do not intubate, and comfort measures only orders were less frequent at the AMC. Mortality 30 days after hospitalization was lower at the AMC (5.1% vs. 12.9%, \(P = 0.003\)) and functional outcome at discharge was more favorable at the AMC.

**Patient outcomes**

Patients with neurologic manifestations experienced longer hospitalization (8 [4, 14] vs. 5 [2, 8] days, \(P < 0.001\)) and, in particular, those with encephalopathy

---

### Table 1

| Variable                        | Odds Ratio | 95% CI   | \(P\) |
|---------------------------------|------------|----------|-------|
| Severe COVID-19 Disease         | 1.51       | 0.61, 3.10 | <0.001|
| Age, years                      | 1.06       | 1.04, 1.08 | <0.001|
| History of Any Neurological Disorder | 3.33  | 1.72, 6.60 | <0.001|
| Time from COVID Onset to Hospitalization, days | 0.91 | 0.85, 0.97 | 0.002|
| Chronic Kidney Disease          | 3.78       | 1.65, 8.65 | 0.002|
| White Blood Cells, 1000/ul      | 0.97       | 0.89, 0.99 | 0.014|
| Number of Neurologic Manifestations at Onset | 1.32 | 1.86, 0.83 | 0.21|
| Peripheral Vascular Disease     | 3.67       | 0.61, 20.44 | 0.10|

### Figure 1

Figure 1. Parsimoniously Adjusted Models of Encephalopathy Occurrence and Favorable Discharge Functional Outcome (Modified Rankin Scale Score 0–2). (A) Parsimoniously adjusted model of encephalopathy occurrence. *A priori* variables included: severe COVID-19 disease; age; history of any neurological disorder; time from COVID-19 onset to hospitalization; serum white blood cell count; number of neurologic manifestations at COVID-19 onset; occurrence of anosmia, dysgeusia, or headache at COVID-19 onset; male sex; C-reactive protein; and D-dimer. In addition to the *a priori* variables, the following variables were univariately associated with encephalopathy at \(P \leq 0.15\) and were considered in the backward stepwise Akaike Information Criteria algorithm used to generate the parsimonious model: history of smoking, dyslipidemia, diabetes mellitus, hypertension, cerebrovascular disease, peripheral vascular disease, chronic kidney disease, heart failure, cancer, and organ transplantation; and procalcitonin level. Only those variables that satisfied the Akaike Information Criteria algorithm for parsimonious model inclusion are listed. (B) Parsimoniously adjusted model of favorable functional outcome at discharge (modified Rankin Scale Score 0 to 2). *A priori* variables included: age, severe COVID-19 disease, occurrence of encephalopathy, male sex, history of any neurological disorder, academic medical center hospitalization, time from COVID-19 onset to hospitalization, and race. In addition to the *a priori* variables, the following variables were univariately associated with encephalopathy at \(P \leq 0.15\) and were considered in the backward stepwise Akaike Information Criteria algorithm used to generate the parsimonious model: ethnicity; history of heart failure, organ transplantation, smoking, dyslipidemia, hypertension, cerebrovascular disease, peripheral vascular disease, coronary artery disease, chronic kidney disease, and cancer. Only those variables that satisfied the Akaike Information Criteria algorithm for parsimonious model inclusion are listed.
had median hospitalizations over threefold longer (Table 1). Discharge functional outcome and mortality was not significantly different between those with and without any neurologic manifestations. No single neurologic manifestation, besides encephalopathy, was significantly associated with worse discharge functional outcome or greater mortality. However, in the parsimoniously adjusted model of discharge functional outcome (Fig. 1B), patients with encephalopathy were independently less likely to experience favorable functional outcome (mRS 0–2; adjusted OR 0.22, 95% CI 0.11–0.42; \( P < 0.001 \)). Other factors associated with favorable functional outcome at discharge, after adjustment were: absence of severe Covid-19 disease, younger age, female sex, absence of pre-existing neurologic disorders, and being hospitalized at the AMC. In a model of mortality adjusting for severe Covid-19 disease, age, and hospitalization at the AMC, the occurrence of encephalopathy
remained independently associated with greater likelihood of death at 30 days after hospitalization (adjusted OR 2.92, 95% CI 1.17, 7.57; \( P = 0.02 \)).

**Discussion**

This study highlights the high frequency and range of neurologic manifestations, which occurred in more than four fifths of Covid-19 patients hospitalized in our hospital network system. These results expand findings of neurologic manifestations in 36.4% of hospitalized Covid-19 patients in China and 57.4% in Europe\(^{16,17}\), albeit with increased prevalence in our US cohort. Differences in frequencies may be caused by genetic factors including polymorphism in expression of the viral receptor angiotensin-converting enzyme 2 (ACE 2) in the nervous system, and possibly, SARS-CoV-2 strain variations.\(^{18}\) In addition, our hospital network system was never stressed beyond capacity due to surge preparation and most patients had moderate disease, with only one quarter developing severe respiratory distress requiring mechanical ventilation.\(^{19}\) This may have allowed for more detailed evaluation and identification of neurologic manifestations. The fact that any neurologic manifestations as a whole were more likely to occur in younger people is surprising, and could potentially be explained by greater clinical emphasis on the risk of respiratory failure than other symptoms in older patients. Alternatively, early neurologic manifestations such as myalgia, headache, or dizziness may have prompted earlier medical care. In contrast, encephalopathy was more frequent in older patients. Risk factors for encephalopathy also included severe Covid-19 disease and history of any neurological disorder or chronic kidney disease. This is consistent with recent literature identifying higher rates of mortality in Covid-19 patients with pre-existing chronic neurological disorders.\(^{20}\)

The increased morbidity and mortality associated with encephalopathy, independent of respiratory severity, parallels previous literature in sepsis-associated encephalopathy and delirium-associated mortality\(^{11,21}\) and emphasizes its relevance in Covid-19. We also found that encephalopathy in Covid-19 was associated with triple the hospital length of stay. Broad recognition and screening for encephalopathy as a contributor to disease severity in Covid-19 may have utility in resource allocation and potential to improve patient outcomes. Furthermore, our findings emphasize the broader need to develop interventions that target encephalopathy as a component of multi-organ system medical illness.

The cause of encephalopathy could not be determined with certainty given the lack of extensive diagnostic neurologic testing for most patients in this study due to ongoing pandemic restrictions. However, the most likely etiology of encephalopathy in patients with Covid-19 is multifactorial, including systemic disease and inflammation, coagulopathy, direct neuroinvasion by the virus, endotheliitis and possibly post-infectious auto-immune mechanisms.\(^{7}\) Additionally, traditional risk factors associated with intensive care unit delirium and encephalopathy also need to be taken into account, including sedation and analgesia doses, disruption of sleep/wake cycles, and infectious complications.\(^{22,23}\) Critical illness encephalopathy, in general, can result from multiple mechanisms or combinations of mechanisms that remain an unresolved area of basic science research.\(^{24}\)

Our hospital network system includes an AMC and nine other hospitals. There was no meaningful difference in severity of disease between the AMC and the other hospitals, but patients at the AMC had better functional outcomes and lower 30-day mortality. One potential explanation for this finding may be related to specialty care, access to resources, and lower rates of do not resuscitate/intubate and comfort measures-only orders. Our AMC is also the largest hospital within the NMHC system with the greatest number of ICU beds, which may confer a survival benefit to critically ill patients with Covid-19.\(^{25}\) A similar difference has been observed in patients with sepsis, who had better outcomes and lower mortality when treated by tertiary versus non-tertiary hospitals.\(^{26}\) Early adoption and implementation of uniform treatment protocols across hospital networks driven by AMCs may be a means to improve outcome and lower mortality of Covid-19 patients that deserves further investigations.

Our study has limitations, including its retrospective nature, and the fact that fewer than 6% of patients were evaluated by neurologists or neurosurgeons. Since most patients were admitted to dedicated Covid-19 wards or ICUs with strict infection control precautions in place, access to brain CT or MRI was not as readily available as for other patients with neurologic diseases. This limited a more complete neurologic work up in many Covid-19 patients. Additionally, patients were cared for at 10 different hospitals and there may have been varying rates of local geographic infection severity. However, this provided us with a more generalized view of the neurologic manifestations in Covid-19 patients and could identify opportunities for regionalized resource allocation and preparedness protocols in a large hospital network system.

Only 9 months into the pandemic, the long-term effects of Covid-19 on the nervous system remain uncertain. Our results suggest that, of all neurologic manifestations, encephalopathy is associated with a worse functional outcome in hospitalized patients with Covid-19, and may have lasting effects.\(^{12}\) Long-term follow-up is necessary to assess the true burden of encephalopathy in...
these patients. Whether milder forms occur in non-hospitalized individuals with Covid-19 who complain of protracted inability to concentrate or decreased short term memory (referred to as ‘brain fog’) warrants further evaluation.27 Prospective cognitive and neurologic-focused evaluations through specialized clinics dedicated to further diagnostic assessment and tailored rehabilitation needs could play a significant role in recovery from this pandemic.

Conflict of Interest
The authors report no conflict of interest pertaining to this publication.

Authors Contributions
All authors contributed to the design of the study, collection and analysis of the data and redaction of the manuscript.

References
1. WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: World Health Organization; 2020 [7/28/2020]; Available from: https://covid19.who.int/.
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–733.
3. Berger JR. COVID-19 and the nervous system. J Neurovirol 2020;26:143–148.
4. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol;19(9):767–783 (2020). https://doi.org/10.1016/S1474-4422(20)30221-0
5. Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous system. Ann Neurol 2020;88:1–11.
6. Leonardi M, Padovani A, McArthur JC. Neurological manifestations associated with COVID-19: a review and a call for action. J Neurol 2020;267:1573–1576.
7. Nath A. Neurologic complications of coronavirus infections. Neurology 2020;94:809–810.
8. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: radiological and laboratory findings. Brain 2020. https://doi.org/10.1093/brain/awa240
9. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 2020;7(10):875–882.
10. Carfi A, Bernabei R, Landi F; Group fGAC-P-ACS. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603.
11. Gofton TE, Young GB. Sepsis-associated encephalopathy. Nat Rev Neurol 2012;8:557–566.
12. Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. N Engl J Med 2013;369:1306–1316.
13. Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990;113:941–948.
14. Devlin JW, Skrobi? Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018;46:e825–e873.
15. Naidech AM, Beaumont JL, Rosenberg NF, et al. Intracerebral hemorrhage and delirium syndromes. Length of stay, function, and quality of life in a 114-patient cohort. Am J Respir Crit Care Med 2013;188:1331–1337.
16. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683–690.
17. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 2020;95:e1060–e1070.
18. Shen Z, Xiao Y, Kang L, et al. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients. Clin Infect Dis2020;71(15):713–720. https://doi.org/10.1093/cid/ciaa203
19. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020;323:1545–1546.
20. Garcia-Azorín D, Martínez-Pías E, Trigo J, et al. Neurological comorbidity is a predictor of death in Covid-19 disease: a cohort study on 576 patients. Front Neurotol 2020;11:781. https://doi.org/10.3389/fneur.2020.00781
21. Witlox J, Eurelings LS, de Jonghe JF, et al. Delirium in intensive care unit. N Engl J Med 2014;30:444–454.
22. Davies NWS, Sharief MK, Howard RS. Infection—associated encephalopathies—their investigation, diagnosis, and treatment. J Neurol 2006;253:833–845.
23. Heming N, Mazeraud A, Verdonk F, et al. Neuroanatomy of sepsis-associated encephalopathy. Crit Care 2017;21:65.
24. Gupta S, Hayek SS, Wang W, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020. https://doi.org/10.1001/jamainternmed.2020.3596
25. Salvaterra GG, Gulek BG, Erdik B, et al. In-hospital sepsis mortality rates comparing tertiary and non-tertiary hospitals in Washington State. J Emerg Med 2018;54:785–792.
27. Perrin R, Riste L, Hann M, et al. Into the looking glass: post-viral syndrome post COVID-19. Med Hypotheses 2020;144:110055.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Additional patient characteristics by presence of neurologic manifestations and encephalopathy.

Table S2. Details of A Priori and Parsimonious Adjusted Binary Logistic Regression Models of Any Neurologic Manifestation, Encephalopathy, and Favorable Functional Outcome at Discharge.

Table S3. Additional Covid-19 Patient Characteristics Comparing Academic Medical Center vs. Other Hospitals.